17th ANNUAL EARLY HEARING DETECTION & INTERVENTION MEETING
March 18-20, 2018 • Denver, CO
3/20/2018 | 3:00 PM - 3:30 PM | Clinical and Hearing Management of Infants Identified on Cytomegalovirus (CMV) Screening with Congenital CMV Infection – What to do With all the Babies? | Quartz A/B
Clinical and Hearing Management of Infants Identified on Cytomegalovirus (CMV) Screening with Congenital CMV Infection – What to do With all the Babies?
With increasing interest in screening for congenital CMV infection (cCMV), many more children with cCMV are being identified. Implementation of targeted CMV screening, within newborn hearing screening, in multiple states along with individual hospitals elsewhere is leading to identification of infants with cCMV that would have previously gone undetected. Approximately 15% of clinically inapparent (asymptomatic) cCMV infants will have hearing loss during early childhood years but less is known about developmental disabilities in the asymptomatic cCMV infant. Current clinical and antiviral treatment recommendations apply to infants with symptomatic cCMV. However, it is unclear what the appropriate clinical evaluation and management is for the asymptomatic cCMV infant who is at risk for CMV sequelae, although to a lesser degree than the infants with symptomatic disease. How should the asymptomatic infant with isolated hearing loss at birth or an infant with asymptomatic infection with no hearing loss at birth be clinically managed? Should all asymptomatic infants undergo full laboratory and neuroimaging evaluations? Is there evidence for treatment of infants with asymptomatic cCMV with antivirals? How often should cCMV infants or children have audiological assessments and until what age? This session will summarize the current literature, data from UAB’s earlier cohort and the CHIMES study to develop a proposed clinical management and hearing algorithm for the asymptomatic cCMV infant. In addition, we will address the gaps in our knowledge where more data are needed for the clinical management of infants with asymptomatic cCMV.
- Review definitions of symptomatic and asymptomatic congenital CMV infection
- Discuss data on congenital CMV infection used to develop a clinical management and hearing algorithm
- Discuss current gaps in our knowledge about asymptomatic congenital CMV infection
Presentation:
15805_8031KarenFowler.pdf
Handouts:
Handout is not Available
Transcripts:
15805_8031ShannonRoss.doc
Presenters/Authors
Karen Fowler
(), University of Alabama at Birmingham (UAB), kfowler@uab.edu;
Karen B. Fowler, DrPH, is a professor in the Department of Pediatrics at the UAB School of Medicine. Her research focuses on the epidemiology, natural history, and pathogenesis of maternal and congenital cytomegalovirus infections and CMV-related hearing loss in children.
ASHA DISCLOSURE:
Financial -
Receives Grants for Other activities from NIH.
Receives Grants for Other activities from NIH.
Nonfinancial -
No relevant nonfinancial relationship exist.
Shannon Ross
(), University of Alabama at Birmingham (UAB), sross@peds.uab.edu;
Dr. Ross is an Associate Professor in the Department of Pediatrics at the UAB School of Medicine. Her research focuses on the natural history and pathogenesis of congenital CMV infection, with special emphasis on translational research studying hearing loss in congenital CMV infection.
ASHA DISCLOSURE:
Financial -
No relevant financial relationship exist.
Nonfinancial -
No relevant nonfinancial relationship exist.
Suresh Boppana
(), University of Alabama at Birmingham (UAB), sboppana@peds.uab.edu;
Dr. Boppana is a Professor in the Department of Pediatrics at the UAB School of Medicine. His laboratory has been interested in the natural history and the pathogenesis of congenital CMV infection and CMV-related hearing loss for over 20 years.
ASHA DISCLOSURE:
Financial -
No relevant financial relationship exist.
Nonfinancial -
No relevant nonfinancial relationship exist.